Takeda Type II diabetes drug shown useful in late-stage trial

09/13/2005 | Wall Street Journal, The

Researchers report that Takeda Pharmaceuticals' Actos proved effective in a late-stage trial in reducing the risk of fatal or serious conditions associated with Type II diabetes. In conjunction with Eli Lilly, Takeda has been developing the drug, which the companies said reduced the combined risk of heart attacks, strokes and death by 16%.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN